New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 10, 2014
06:38 EDTVRTXVertex a buy into Phase 3 data for VX-809, says Deutsche Bank
Deutsche Bank said it would be a buyer of Vertex shares into the company's mid-2014 Phase 3 data for VX-809. The firm expects the primary endpoint to be hit and thinks shares could trade to $103-$111 on good data. Deutsche says shares of Vertex could trade down to $30-$35 with a Phase 3 failure. It has a Buy rating on the stock with a $103 price target.
News For VRTX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 13, 2015
15:22 EDTVRTXVertex CEO says 'way too early' to talk about pricing for new CF combo drug
Vertex CEO Jeff Leiden speaking on CNBC.
07:36 EDTVRTXVertex price target raised to $146 from $125 at Piper Jaffray
Piper Jaffray raised its price target for Vertex Pharmaceuticals shares to $146 citing continued Kalydeco growth after the company issued 2015 guidance. Piper reiterates an Overweight rating on Vertex.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use